FXYD3 and cancer: Previous investigations have revealed the aberrant expression of FXYD3 in diverse cancers, including prostate cancer [12], colorectal cancer [13], esophageal squamous carcinoma [14], breast cancer [15], pancreatic cancer [16], glioma [17] and lung cancer [18].